Australia Markets close in 30 mins
  • ALL ORDS

    7,206.90
    +64.70 (+0.91%)
     
  • ASX 200

    7,022.00
    +66.60 (+0.96%)
     
  • AUD/USD

    0.6697
    +0.0023 (+0.3496%)
     
  • OIL

    69.50
    +0.17 (+0.25%)
     
  • GOLD

    1,941.50
    +0.40 (+0.02%)
     
  • BTC-AUD

    42,172.15
    +403.76 (+0.97%)
     
  • CMC Crypto 200

    616.18
    +11.13 (+1.84%)
     
  • AUD/EUR

    0.6215
    +0.0022 (+0.36%)
     
  • AUD/NZD

    1.0793
    +0.0028 (+0.26%)
     
  • NZX 50

    11,586.93
    +55.63 (+0.48%)
     
  • NASDAQ

    12,741.44
    +178.83 (+1.42%)
     
  • FTSE

    7,536.22
    +132.37 (+1.79%)
     
  • Dow Jones

    32,560.60
    +316.02 (+0.98%)
     
  • DAX

    15,195.34
    +261.96 (+1.75%)
     
  • Hang Seng

    19,629.21
    +370.45 (+1.92%)
     
  • NIKKEI 225

    27,504.58
    +558.91 (+2.07%)
     

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

1 Green Flag and 1 Red Flag for Fulgent Genetics After Earnings

Fulgent Genetics (NASDAQ: FLGT) has been a fascinating company to watch over the past few years. While that's an impressive market beat, there was a point in early 2021 when Fulgent's stock was up over 1,300%. This wild stock movement was spurred on by incredible revenue growth due to Fulgent's ability to pivot to providing COVID-19 tests early in 2020.